iTeos Therapeutics, Inc.
ITOSDelisted Aug 29, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001808865
iTeos Therapeutics, Inc. was delisted on Aug 29, 2025; its insiders filed their last Form 4 on Aug 29, 2025; 137 institutions reported holding it in 13F filings for Q2 2025, worth $377.0M in total; no superinvestor held it.
13F holders, Q4 2021
Institutional positions in iTeos Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 118
- +42 vs. Q3 2021
- Shares held
- 33.4M
- +2.28M (+7.3%) vs. Q3 2021
- Total value
- $1.55B
- +$713.1M (+84.8%) vs. Q3 2021
- New holders
- 46
- 37 more added
- Sold out
- 4
- 24 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ITOS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 1 | $2.35K |
| Q2 2025 | 137 | $377.0M |
| Q1 2025 | 132 | $220.7M |
| Q4 2024 | 137 | $262.2M |
| Q3 2024 | 151 | $373.3M |
| Q2 2024 | 139 | $536.8M |
| Q1 2024 | 136 | $471.2M |
| Q4 2023 | 138 | $383.4M |
| Q3 2023 | 144 | $388.6M |
| Q2 2023 | 146 | $460.4M |
| Q1 2023 | 153 | $488.9M |
| Q4 2022 | 146 | $707.3M |
| Q3 2022 | 143 | $698.2M |
| Q2 2022 | 153 | $768.1M |
| Q1 2022 | 159 | $1.17B |
| Q4 2021 | 118 | $1.55B |
| Q3 2021 | 77 | $841.3M |
| Q2 2021 | 83 | $755.8M |
| Q1 2021 | 81 | $1.03B |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding iTeos Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 373,788 | $17.4M | 0.00% | +26,425+7.6% | Added |
| Octagon Capital Advisors LP | 450,776 | $21.0M | 4.08% | +450,776 | New |
| Artal Group S.A. | 544,047 | $25.3M | 0.74% | −450,000−45.3% | Reduced |
| Candriam Luxembourg S.C.A. | 757,327 | $35.3M | 0.23% | +232,083+44.2% | Added |
| State Street Corp | 763,351 | $35.5M | 0.00% | +441,244+137.0% | Added |
| FMR LLC | 795,481 | $37.0M | 0.00% | −9,600−1.2% | Reduced |
| Tang Capital Management LLC | 937,500 | $43.6M | 8.78% | +37,500+4.2% | Added |
| Citadel Advisors LLC | 998,941 | $46.5M | 0.05% | +23,523+2.4% | Added |
| Vanguard Group Inc | 1,060,810 | $49.4M | 0.00% | +441,779+71.4% | Added |
| Rubric Capital Management LP | 1,172,320 | $54.6M | 2.58% | +183,637+18.6% | Added |
| EcoR1 Capital, LLC | 1,303,157 | $60.7M | 1.94% | 00.0% | Unchanged |
| Alliancebernstein L.P. | 1,305,213 | $60.8M | 0.02% | −29,868−2.2% | Reduced |
| BlackRock Inc. | 1,613,228 | $75.1M | 0.00% | +54,992+3.5% | Added |
| MPM Oncology Impact Management LP | 1,844,727 | $85.9M | 15.66% | −262,365−12.5% | Reduced |
| RTW Investments, LP | 2,353,015 | $109.6M | 1.60% | 00.0% | Unchanged |
| MPM Asset Management LLC | 2,885,470 | $134.3M | 29.03% | −405,241−12.3% | Reduced |
| Boxer Capital, LLC | 4,345,016 | $202.3M | 8.05% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 4,417,259 | $205.7M | 3.63% | 00.0% | Unchanged |
| 683 Capital Management, LLC | 0 | $0 | 0.00% | −200,413−100.0% | Sold out |
| Mirabella Financial Services LLP | 0 | $0 | 0.00% | −14,280−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −9,888−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −805−100.0% | Sold out |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |